Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Corn

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cancer|October 29, 2009
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysisEric Jonasch, Paul Corn, Lance C Pagliaro, et al.
Clinical Genitourinary Cancer|August 29, 2016
Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With PazopanibMarc R Matrana, Ali Baiomy, Matthew Campbell, et al.
The Journal of Urology|April 4, 2024
Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial CarcinomaSurena F Matin, Mehrad Adibi, Amishi Y Shah, et al.
Cancer|July 29, 2010
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinomaToni K Choueiri, Zita Dubauskas Lim, Michelle S Hirsch, et al.
European Urology|September 7, 2015
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial CancerDavid J McConkey, Woonyoung Choi, Yu Shen, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2024
Polyploid cancer cells reveal signatures of chemotherapy resistanceMichael J Schmidt, Amin Naghdloo, Rishvanth K Prabakar, et al.
Oncogene|November 23, 2024
Polyploid cancer cells reveal signatures of chemotherapy resistanceMichael J Schmidt, Amin Naghdloo, Rishvanth K Prabakar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2015
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate CancersAna M Aparicio, Li Shen, Elsa Li Ning Tapia, et al.
Brachytherapy|January 4, 2025
Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrencesComron Hassanzadeh, Osama Mohamad, Teresa Bruno, et al.
Cancers|December 23, 2023
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) EnvironmentsPaul V Viscuse, Rebecca S Slack-Tidwell, Miao Zhang, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cancer|October 29, 2009
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysisEric Jonasch, Paul Corn, Lance C Pagliaro, et al.
Clinical Genitourinary Cancer|August 29, 2016
Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With PazopanibMarc R Matrana, Ali Baiomy, Matthew Campbell, et al.
The Journal of Urology|April 4, 2024
Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial CarcinomaSurena F Matin, Mehrad Adibi, Amishi Y Shah, et al.
Cancer|July 29, 2010
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinomaToni K Choueiri, Zita Dubauskas Lim, Michelle S Hirsch, et al.
European Urology|September 7, 2015
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial CancerDavid J McConkey, Woonyoung Choi, Yu Shen, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2024
Polyploid cancer cells reveal signatures of chemotherapy resistanceMichael J Schmidt, Amin Naghdloo, Rishvanth K Prabakar, et al.
Oncogene|November 23, 2024
Polyploid cancer cells reveal signatures of chemotherapy resistanceMichael J Schmidt, Amin Naghdloo, Rishvanth K Prabakar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2015
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate CancersAna M Aparicio, Li Shen, Elsa Li Ning Tapia, et al.
Brachytherapy|January 4, 2025
Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrencesComron Hassanzadeh, Osama Mohamad, Teresa Bruno, et al.
Cancers|December 23, 2023
Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) EnvironmentsPaul V Viscuse, Rebecca S Slack-Tidwell, Miao Zhang, et al.
Pageof 4